(R)-2-(2,2-二溴乙烯基)-1-吡咯烷羧酸1,1-二甲基乙基酯 | 130418-88-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (R)-2-(2,2-二溴乙烯基)-1-吡咯烷羧酸1,1-二甲基乙基酯
• 英文名称: (R)-2-(2,2-dibromoethenyl)-1-pyrrolidinecarboxylic acid 1,1-dimethylethyl ester
• 英文别名: 2(R)-(2,2-dibromoethenyl)-N-(tert-butoxycarbonyl)pyrrolidine；tert-butyl (2R)-2-(2,2-dibromovinyl)pyrrolidine-1-carboxylate；tert-butyl (2R)-2-(2,2-dibromoethenyl)pyrrolidine-1-carboxylate
• CAS: 130418-88-1
• 化学式: C₁₁H₁₇Br₂NO₂
• 分子量: 355.069
• InChiKey: JXIYXIWBJYCVST-MRVPVSSYSA-N

物化性质

• 熔点：
  65-66 °C
• 沸点：
  350.1±32.0 °C(Predicted)
• 密度：
  1.670±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-2-(2,2-二溴乙烯基)-1-吡咯烷羧酸1,1-二甲基乙基酯 在 盐酸 、 仲丁基锂 、 溶剂黄146 、 copper(l) chloride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 (R)-1-acetyl-2-<3-(1-pyrrolidinyl)-1-propynyl>pyrrolidine
  参考文献：
  名称：

  Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogs of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5)

  摘要：

  A series of optically pure 2-[substituted-3-aminopropynyl]pyrrolidine derivatives, which are restricted-rotation analogues of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5, compound 1), have been prepared from d- and l-proline. The compounds when tested in a series of in vitro muscarinic assays [[3H]CD (cortex), [3H]QNB (cortex), [3H]PZ (cortex), [3H]QNB (heart), [3H]QNB + GppNHp (heart)] were found to have weaker muscarinic properties than compound 1. The decrease in affinity was attributed to the increased size of the molecule resulting from the addition of a methylene group to form the pyrrolidine ring. The use of optically active compounds provided a more detailed examination of the complex pharmacological effects of the flexible muscarinic agent 1. The R enantiomers in the acetamide derivatives 12b, 12d, and 12f had a 5-10-fold greater affinity for the muscarinic receptor than the corresponding S enantiomers. A 5-fold difference or less found in the (R)- and (S)-carbamate derivatives 9, 15, and 16 suggested close overlap of the two enantiomers in the receptor binding domain. The affinity differences found in the enantiomeric acetamido derivatives when compared to those of the carbamate analogues may be the result of limited rotation of the acetamido group.

  DOI：

  10.1021/jm00174a015
• 作为产物：
  描述：

  N-(tert-butoxycarbonyl)-D-proline 在 dimethyl sulfide borane 、 4 A molecular sieve 、 溶剂黄146 、 三苯基膦 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 3.0h， 生成 (R)-2-(2,2-二溴乙烯基)-1-吡咯烷羧酸1,1-二甲基乙基酯
  参考文献：
  名称：

  Chemical and biochemical studies of 2-propynylpyrrolidine derivatives. Restricted-rotation analogs of N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5)

  摘要：

  A series of optically pure 2-[substituted-3-aminopropynyl]pyrrolidine derivatives, which are restricted-rotation analogues of the muscarinic agent N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide (BM-5, compound 1), have been prepared from d- and l-proline. The compounds when tested in a series of in vitro muscarinic assays [[3H]CD (cortex), [3H]QNB (cortex), [3H]PZ (cortex), [3H]QNB (heart), [3H]QNB + GppNHp (heart)] were found to have weaker muscarinic properties than compound 1. The decrease in affinity was attributed to the increased size of the molecule resulting from the addition of a methylene group to form the pyrrolidine ring. The use of optically active compounds provided a more detailed examination of the complex pharmacological effects of the flexible muscarinic agent 1. The R enantiomers in the acetamide derivatives 12b, 12d, and 12f had a 5-10-fold greater affinity for the muscarinic receptor than the corresponding S enantiomers. A 5-fold difference or less found in the (R)- and (S)-carbamate derivatives 9, 15, and 16 suggested close overlap of the two enantiomers in the receptor binding domain. The affinity differences found in the enantiomeric acetamido derivatives when compared to those of the carbamate analogues may be the result of limited rotation of the acetamido group.

  DOI：

  10.1021/jm00174a015

文献信息

• [EN] MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS MACROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASE TRK ET LEURS UTILISATIONS
  申请人：ANGEX PHARMACEUTICAL INC

  公开号：WO2019094143A1

  公开（公告）日：2019-05-16

  The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

  本公开描述了新颖的TRK激酶抑制剂及其制备方法。还描述了包含这种TRK激酶抑制剂的药物组合物以及使用它们治疗癌症、感染性疾病和其他疾病的方法。
• [EN] 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES DE PHENYLE 1,3,5-SUBSTITUES UTILES COMME INHIBITEURS DE LA BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2005103020A1

  公开（公告）日：2005-11-03

  The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及1,3,5-苯基取代衍生物化合物，这些化合物是β-分泌酶的抑制剂，可用于治疗β-分泌酶参与的疾病，例如阿尔茨海默病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗β-分泌酶参与疾病中的用途。
• Ligands for Brain Cholinergic Channel Receptors: Synthesis and in Vitro Characterization of Novel Isoxazoles and Isothiazoles as Bioisosteric Replacements for the Pyridine Ring in Nicotine
  作者：David S. Garvey、James T. Wasicak、Richard L. Elliott、Suzanne Lebold、Ann-Marie Hettinger、George M. Carrera、Nan-Horng Lin、Yun He、Mark W. Holladay

  DOI：10.1021/jm00052a005

  日期：1994.12

  (S)-nicotine (2a) in a preparation of whole rat brain. However, in a paradigm measuring the evoked release of [3H]dopamine from a preparation of rat striatum, there were differences in the agonist potencies and efficacies of these analogues relative to 2a. The differences in agonist potency observed between compounds of comparable binding potency may be due to differences in ligand interactions with various

  激活神经元烟碱型乙酰胆碱受体（nAChRs）的配体代表了姑息治疗与阿尔茨海默氏病（AD）相关的记忆丧失症状的潜在方法。基于此方法，制备了一系列新颖的3,5-二取代异恶唑和异噻唑，并在体外作为神经元nAChR的胆碱能通道激活剂（ChCA）进行了评估。发现在整个大鼠脑的制备中，许多3-取代的5-（2-吡咯烷基）异恶唑具有与（S）-尼古丁（2a）相当的纳摩尔结合亲和力。然而，在测量从大鼠纹状体制剂中诱发的[3H]多巴胺释放的范例中，这些类似物相对于2a的激动剂效力和功效存在差异。
• 1-substituted-2-(3-amino-1-propynyl)pyrrolidine derivatives
  申请人：American Cyanamid Company

  公开号：US05001142A1

  公开（公告）日：1991-03-19

  Compounds of the formula: ##STR1## pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of central cholinergic disfunction in a mammal are disclosed.

  该公式化合物：##STR1## 揭示了含有这些化合物的药物组合物以及使用这些化合物治疗哺乳动物中枢胆碱能功能障碍的方法。
• 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5
  申请人：BRATT Emma

  公开号：US20090111822A1

  公开（公告）日：2009-04-30

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新化合物，其制备方法，它们在治疗中的使用以及包含这些新化合物的制药组合物。